A 2026 case report describes a 34-year-old man with obesity and alcohol use disorder whose semaglutide treatment for weight loss was associated with a marked drop in drinking over 10 months, with his AUDIT score falling from 27 to 7 and alcohol use dropping from about 15 drinks per week to half a beer per month. The authors frame this as a promising but preliminary finding that adds to growing evidence on GLP-1 drugs and alcohol use, while also stressing that this was a single case and that better AUD screening in family medicine remains important.